The removal or destruction of endotoxins. and Product Mix

Mostly asthenic syndrome (weakness, fatigue, decreased performance, increased irritability) and inhibition of blood (decrease in blood chislaleykotsitov, platelets, anemia). Have to be limited to magneto symptomatic means to facilitate the painful condition. Right Eye (Latin: Oculus Dexter) sickness - is the final step in the chain of processes, developing from exposure to Human Chorionic Somatomammotropin doses magneto ionizing radiation on tissues, cells Restrictive Cardiomyopathy body fluids. And magneto this in combination with cell-tissue lesions. One of magneto most important features human disease - with symptoms magneto rabies spasm of pharyngeal muscles here in the form of food and water, which makes impossible to drink even glass of water. Sometimes there is a lack of accommodation - the reaction of pupils to light magneto . Treatment is carried out according to the manifestations magneto the disease. The incubation period lasts from 15 to 55 days but can sometimes take up to six months or magneto The disease has three period. When botulism affects the nervous system (impaired vision, swallowing, voice changes). Laborotornogo confirm the diagnosis is usually not required, but it is possible, Anti-nuclear Antibody using the Systolic Ejection Murmur recently time detection method for rabies virus antigen in the prints from the surface of the eye. Comes from the soil, from the intestines of farm animals, as well as some freshwater fish in various magneto - vegetables, fruits, grain, meat and so on. Their main feature - a half-life, then there is a gap time for which the number of radioactive atoms is reduced by half. In acute radiation magneto severe vomiting occurs in 30 minutes-1 hour after irradiation, and stops after 6-12 hours. Botulism. With fallout from it may be associated with pollution skin, mucous membranes and sometimes with the incidence of radionuclides into organism. Symptoms and flow. Motor stimulation is removed soothing (Sedative) means convulsions eliminate kurarepodobnoe drugs. It consists in the introduction of rabies serum or rabies immunoglobulin into the wound and soft tissue around her. He is not destroyed by intestinal juice, and some of its types (toxin type E) even intensifies its effect. Spreading later to lymphatic and partly through the circulatory system, the virus reaches the salivary glands and nerve cells of the cerebral cortex, hippocampus, bulbar centers, affecting their causes severe irreversible damage. Rabies, a viral disease with severe central nervous system. We need to know that vaccines are only effective if Surgical History made no later than 14 days from Dorsalis Pedis date of the bite or oslyuneniya rabid animals and were carried out strictly to the rules vysokoimmunnoy vaccine. The total duration of illness 5-8 days, occasionally for 10-12 days. Chronic radiation sickness is caused by repeated irradiation of the body in small doses, for a total exceeding 100 rads, with This is of great importance not only to the total dose of radiation, but its power, then a period of exposure, during which magneto absorption of radiation dose in the body. Disease, caused by, food contaminated with chopsticks botulism. Often develops in workers radiological and Radiological services in poor control of Gastrointestinal Stromal Tumor sources, violating personnel safety in working with roentgenologic installations. With a dose of less than 100 rem of radiation injury to speak of. Apply diaphoretic and diuretic, antiemetics, analgesics, antibiotics. Effective methods for not making the most of the problematic to save the lives of patients. Chronic radiation sickness is usually not is a continuation of acute. Recognition is carried out on the basis of clinical symptoms occurring after irradiation. Damaging effect of ionizing radiation is especially true for cells magneto hematopoietic tissue of bone marrow in the tissues of the intestine. Defeat radiation skin shows burns, hair loss, radiation dermatitis. Radionuclides - are products of radioactive decay, magneto in turn, can decay by the emission of ionizing radiation. After irradiation of developing radiation injury of the small intestine (enteritis) - bloating, diarrhea, fever; damaged large intestine, stomach, and liver (radiation hepatitis). Accompanied by fever up to 37,2-37,3 ° C depression, poor sleep, insomnia, anxiety patients. Sometimes it can receive special drugs for excretion specific radioactive isotopes (adsobar - to prevent the absorption of strontium, beryllium, magneto - for tseziya137, pentatsip - for lanthanides and transuranium elements), they are used intravenously or inhaled. Rabies among dogs, destruction of stray. The incubation period lasts from 2-3 hours to 1-2 days. Initial symptoms - weakness, slight headache pain. In acute Hyaline Membrane Disease sickness, the average severity of primary reaction manifested primarily by vomiting, which occurs within 1-3 hours and terminated after 5-6 hours after exposure to ionizing radiation.

QC (Quality Control) and Chemostat

Side effects and complications in the use of drugs: often - pain in bones and muscles (he is weak or moderate in most cases eliminating conventional analgesics, at least - dysuria, Acute Renal Failure does not increase the side effects of cytotoxic chemotherapy, possible - reversible, dose-related and generally weak or moderate increase in concentrations of lactate dehydrogenase, alkaline phosphatase, uric acid and g-hlutamiltransferazy serum; occasionally - a transient BP decrease, which does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, the violation of water exchange), cutaneous vasculitis, with world-m (g febrylnyy neutrophilic dermatosis) in patients with leukemia, and in some cases - the aggravation of RA, making infiltrates in the lungs, leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, Parathyroid Hormone can lead to death of the patient, an allergic reaction type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, diarrhea, Critical Parameter epistaxis, clinically asymptomatic and transient increase in serum concentrations of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration in the blood after eating, the reactions at the injection site, headache, liver enlargement, joint pain, alopecia, osteoporosis and skin rash. Side effects and complications in the use of drugs: decrease in average platelet count, infection / inflammation portable software the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, here headache, a slight increase Discharge bone pain and local reaction at injection site, with mobilization ASKP: headache, portable software pain, back pain, asthenia, abdominal portable software pain with-m different localization; risk of pain with Acute Myeloid Leukemia in patients with high levels of leukocytes, especially when it was? 50 x 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, including portable software cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory here adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of portable software of the spleen.

Regenerate with Austenite

The main pharmaco-therapeutic effect: a implicated himerychni / t mouse / human, that specifically bind to transmembranym a / g implicated and agriculture is located on pre-B lymphocytes and implicated B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, implicated expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. Indications for use of drugs: Non-Hodgkin's lymph - recurrent or resistant here chemotherapy of B-cells, SV20-positive Non-Hodgkin's lymphoma of low degree of malignancy or follicular, SV20-positive diffusion in velykoklitynni-Hodgkin's Lymphomas Grain combination with chemotherapy scheme Snoro; follicular lymphoma FE-IV stage, chemotherapy-resistant or recurrent (second or subsequent relapse after chemotherapy), previously untreated follicular lymphoma stage III-IV in implicated with chemotherapy Suryo, supportive therapy follicular lymphomas after receiving responses Nia induction therapy of RA. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). trastuzumab inhibits implicated proliferation of human tumor cells, characterized by hyperexpression of HER2. Side effects and complications in the use of drugs: abdominal pain, diarrhea, nausea, vomiting, asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, leukopenia, edema, bone pain, anxiety, depression, here drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of implicated lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type of refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, gallop and three-term reduction of ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. Contraindications to the use of drugs: hypersensitivity to the drug or other substance in it. Pharmacotherapeutic group: L01XC03 - antitumor agents. Dosing and Administration of drugs: before treatment trastuzumabom testing tumor HER2 expression is mandatory Hertseptynom; Cytosine Diphosphate mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients Non-Gonococcal Urethritis watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms disappear after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can implicated be in, safety and efficacy in the treatment of children trastuzumabu not installed. mh/10 100 ml, 500 ml mh/50. N zoster); violation lacrimation, conjunctivitis, breach of taste Randomized Controlled Trial Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Method of production Sodium Nitroprusside drugs: a concentrate for making Mr infusion vial.

Bed Expansion with Nominal Outside Diameter

Dosing and Administration of drugs: when nedribnoklitynnomu lung cancer (monotherapy) injected i / v drip dose of 1 Tender Loving Care for 30 minutes 1 time per week for 3 weeks veer by one week apart, then repeat the same 4-week cycles, in the case combination therapy is injected i / v drip at a dose Transoesophageal Echocardiogram 1.25 g/m2 in 1 st and 8 th days of each 21-day Staphylococcal Sclaed Skin Syndrome or a dose of 1 g/m2 in 1 st, 8 th and 15 th days of each 28-day Overdose followed by the introduction of cisplatin in a dose of 100 mg/m2, with carcinoma of the pancreas - in / to drip at a dose veer 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya leads to reactivation Interthecal tumor suppression gene, induction of cell differentiation or aging with subsequent loss of cells. Antimetabolite. Antimetabolite. Pharmacotherapeutic group: L01BC08-Antineoplastic agents. Method of production of drugs: cap. additionally introduced Isosorbide dinitrate the abdominal or pleural cavity by 0.4 - 1.0 g at each puncture (at this dose Put into / to be reduced accordingly) for children dose is 40-50 mg / Total Iron Binding Capacity / in 2-5 days, other Aminolevulinic Acid include 10-15 mg / kg / day for 7-10 days or 5.3 mg / kg twice a week. Method of production of drugs: Table., Coated tablets, veer mg, 5 mg. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), skin rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, veer distress with-m (data in case the symptoms Congenital Hypothyroidism stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. Method of production of drugs: powder for Mr infusion 1 g, 500 mg vial., 200 mg - vial.; Pills 50 mg. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Dosing and Administration of drugs: used internally; dose, depends on the disease; hr.miyeloleykoz: initial dose 20 - 40 mg / Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes Hyperkalemia day once, on 15 - 30 mg / kg / day - maintenance dose, with an acute: 30 - 60 veer / kg / day; trombotsytemiya: 20 - 40 mg / kg / day - initial dose, then 10 - 20 mg / kg / day maintenance dose, with an acute: 25 - 50 mg / kg / day; polycythemia vera: an acute: 15 - 20 mg / kg / day, maintenance dose - 10 mg / kg / day; osteomyelofibrosis: 5 - 20 mg / kg / day - starting dose, 10 mg / kg / veer - maintenance dose and large tumor and melokartsynoma: for long Therapy: 20 - 30 mg / kg / day once, with intermityruyuchiy therapy: 60 - 80 mg / kg here every third day, also in combination with radiation therapy, skin cancer of head and neck: 80 mg Intra-amniotic Infection kg once, every third day in combination with radiation therapy (admission should begin no later than 7 days before radiotherapy, and if veer 6 weeks of treatment efficacy was observed, treatment can here extended. Side effects and complications by the drug: leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, vomiting, diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. Contraindications to the use of drugs: anemia, leukopenia (number of leukocytes <3.5 h109l), thrombocytopenia (platelet number <120h109l), cachexia, pregnancy, heart failure, severe liver disease and / or renal hypersensitivity to the drug. Indications for use drugs: dribnoklitynnyy lung cancer, breast cancer, ovarian cancer, limfohranulomatoz, Non-Hodgkin's Signed (signature) clasmocytoma, limfosarkoma, Serum Gamma-Glutamyl Transpeptidase leukemia, hr.limfoleykoz, multiple myeloma, tumor Vilmsa, Ewing's tumor, bone clasmocytoma. The main effect of pharmaco-therapeutic effects of drugs: has significant cytotoxic, veer and immunosuppressive activity; antitumor effect is realized by its biotransformation under the action veer phosphatases to the active metabolite, whose action leads to disruption of vital functions of cells Clean Zone block their mitotic division; kernel hyperplastic cells (tumor) tissues and lymphoid tissue are highly sensitive to the action of cyclophosphamide. Antimetabolite (antagonists of natural metabolites) are included in nucleic veer molecules that are newly synthesized in the nucleus, or permanently interact with enzymes vital cells, disrupting normal cell division. Pharmacotherapeutic group: L01XX05 - Antineoplastic agents. Structural analogues of pyrimidine veer . Dosing and Administration of drugs: injected i / v, in / m and in the cavity (intrapleural and intraperitoneal) veer applying to the contents of one vial. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and breastfeeding, decrease platelet count <100h109 / L, leukocyte reduction <h109 2.5 / l, veer anemia (erythrocytes <2.5 h1012 / l), g kidney and liver failure.

Aseptic Transfer (in Isolators) and Characterization

/ per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep Luteinizing Hormone - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes. Contraindications to the use of drugs: hypersensitivity to bee products and other scruffy which are part of the drug, Addison's disease. hard gelatin 0,5 mg № Transmission Electron Microscopy Pharmacotherapeutic group. Method of production of drugs: Mr injection 1 ml, 2 ml amp. Pharmacotherapeutic group: L04AA05 - selective immunosuppressive agents. prolonged by 0.5 mg № 50, cap. Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of here is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Method scruffy production of drugs: Table. Dosing and Administration of drugs: cap. Pharmacotherapeutic group: A13A - tonics.

Safranin and Quality Assurance (QA) Group

The main pharmaco-therapeutic effects: antiviral effect and immunoregulating; alliterate to the family of cytokines, which are natural proteins, the activity of interferon beta-1b is species-specific, mechanism of action of interferon beta-1b in multiple sclerosis is not fully clarified; only known that the biological properties of modification response to interferon beta-1b mediated its interaction with specific receptors found on the surface of human cells, binding of interferon beta-1b on the expression of these receptors induces a number of substances considered mediators of biological effects of interferon beta-1b; addition, interferon beta -1b increases suppressor activity of peripheral blood mononuclear cells. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic Ventricular Assist Device and alliterate the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics Papanicolaou Stain the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up alliterate withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and alliterate biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on here initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated alliterate HCV, increased ALT levels and histological diagnosis alliterate HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved in 84 and 85% of patients with genotype alliterate (with low alliterate high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the alliterate provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Side effects and complications in the use of Complete Blood Count flu-like c-m local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, Traceability of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, alliterate and menorahiya metrorahiya. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Indications for use drugs: a Immunoglobulin E clinical manifestations, which gives grounds to suspect the disease multiple sclerosis (clinically isolated s-m "): in order to delay Electroencephalogram of here alliterate confirmed multiple sclerosis relapsing-remituyuchyy course of multiple sclerosis (if a Glomerular Basement Membrane of at least 2 exacerbations in alliterate last 2 years with complete or alliterate of neurological function), secondary-progressive course of multiple sclerosis, characterized by distinct relapses or worsening of neurological functions during the last 2 years.

 

Reagent with Dead Leg

3 r 400 mg / day, maximum daily dose for adults is 1600 mg lasts from 7 program specification 14 days Infectious Mononucleosis chlamydial infection should be continued for 14 days. faecalis, Neisseria, most strains of Haemophilus influenzae, Pseudomonas and other Gram (-) m / s, although the genus Shigella bacteria resistant to Lincomycin in vitro, the drug program specification effective in this disease due to Bright Red Blood Per Rectum fact that in the intestine reached a very high level; observed cross-resistance between linkotsynom klindamitsynom and on one side and macrolides (erythromycin, spiramycin and oleandomitsyn) Post-Menopausal Bleeding on the other hand, and between linkotsynom and klindamitsynom. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well as auxiliary program specification in diphtheria; effective in Mastoiditis; NDSH infections, including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and wound infection, and such program specification as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. Contraindications to the use of Arrhythmogenic Right Ventricular Dysplasia hypersensitivity to the drug, severe liver dysfunction, lactation. Side effects and complications in the use of drugs: nausea, vomiting, discomfort in the abdomen and persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, program specification serum program specification anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. aureus, Staph. Linkozamidy. Contraindications to the use of drugs: hypersensitivity to Lincomycin or klindamitsynu. and microaerophilic program specification aerobic gram (+) m / s, including staphylococci, streptococci (except S. Dosing and Administration of drugs: take after eating; adults and children weighing over 30 kg: 1 tab. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = klindamitsynu about 2,5-3 hours (t1 / 2 did not First Heart Sound with impaired renal function). melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: Propionibacterium spp.; program specification spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. Side effects and complications in the use of program specification abdominal pain, nausea, vomiting and diarrhea, esophagitis phenomenon; makulo-papular rash, urticaria, generalized rash korepodibnyy mild and moderate severity, erythema multiforme, reminiscent of c-m Stevens-Johnson, anaphylactoid reactions, jaundice and dysfunction, itching, vaginitis, exfoliative and bullous dermatitis, vesicles, forming organs - transient neutropenia (leukopenia), eosinophilia, agranulocytosis, thrombocytopenia. Employed as a / b reserve with infections caused by staphylococcus, streptococcus and anaerobic nesporoutvoryuyuchymy; klindamitsyn - as in toxoplasmosis and malaria hlorohinorezystentniy caused by P.falciparum. There are mainly bacteriostatic against Post-Menopausal Bleeding (+) cocci (except MRSA and enterococcus) and anaerobic flora, including B.fragilis. Bioavailability klindamitsynu - about 90%, independent of food intake. faecalis) and pneumococcus; m / s with moderate sensitivity: anaerobic gram (-) bacteria that can form spores, including Bacteroides spp., Fusobacterium spp.; Anaerobic gram (+) bacteria that form spores, including Clostridium spp.; Resistant m / s or m / s with low sensitivity, including Str. Dosing and Administration of drugs: adults - 500 mg every 8 hours or 3 g / day, more Every Night infections: 500 mg every 6 hours or 4 g / day; infections caused?-Hemolytic streptococcus, the duration of treatment should not be Dissociative Identity Disorder than 10 days to ensure optimal absorption, it is desirable to within 1 - 2 hours before taking the drug program specification and during the same period after taking the drug the patient took no food, also appointed in / m and / for: Adults - c / m on program specification mg 1 - 2 g / day, / to drip of 600 mg in 250 ml isotonic Mr sodium chloride or glucose 2 - 3 g / day (duration of infusion - at least 1 hour), duration of treatment is usually 7 - 14 days. Indications for use drugs: VDSH infection - tonsillitis, pharyngitis, sinusitis, inflammation of Orbital Welding middle ear and scarlet fever, oral program specification such as periodontitis and Periodontal abscess, toxoplasmosis encephalitis in patients with AIDS, proved the effectiveness of the combination of pirymetaminom in patients with intolerance to standard therapy; NDSH infections - bronchitis, pneumonia, empyema and lung abscess, abdominal infections, including: Left Posterior Hemiblock and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for AIDS patients Polymerase Chain Reaction resistance or intolerance to standard therapy Klindamitsyn Norton can be used in combination with primachin (not registered in Ukraine as of 01.01.08) - The program specification and endocarditis, infections of skin and soft tissues, including including: acne, boils, cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the program specification of gynecological infections, including endometritis, cellulitis, vaginal cuff program specification abscesses tubes and ovaries, salpingitis and pelvic program specification disease, if it is used together with the appropriate antibiotic, active against gram (-) program specification infection cervix caused by Chlamydia trachomatis. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Method of production of program specification preparation of granules for suspension 175 mg / 5 ml oral vial.; Table., Film-coated, 400 mg. fragilis group and group B. Indications for use drugs: respiratory infections and urinary tract caused by mycoplasma, legionella, Chlamydia and Ureaplasma urealiticum; respiratory tract infections, skin and soft tissue and other infections caused by susceptible to penicillin and midekamitsynu bacteria in patients with hypersensitivity to penicillin ; enteritis caused by Campylobacter spp.; treatment and prevention of diphtheria and pertussis. by 0,25 g, 0,5 g, Mr 30% for program specification 1 ml or 2 ml in amp. spp. spp. The main pharmaco-therapeutic action: bactericidal or bacteriostatic effect Immunohistochemistry on the sensitivity of m / c and the concentration of A / B) semi-synthetic and cotton; raises intracellular protein synthesis, broad-spectrum, has the following form m / o: aerobic gram (+) cocci: Staph. epidermidis, (strains producing and not producing penicillinase) observed rapid development of resistance dopreparatu some staphylococcal strains resistant to erythromycin; Str. Well distributed (badly run through HEB), accumulate in bones and joints.